Nick Jonas discusses his diabetes on dLife
WESTPORT, Conn. Pop sensation Nick Jonas of the Jonas Brothers has agreed to an exclusive interview to discuss his four-year struggle with Type 1 diabetes. The interview is set to air on dLIfeTV Sunday, July 19 at 7 p.m. on CNBC.
Jonas has succeeded in integrating diabetes management into the daily lifestyle of a pop music superstar. “Sometimes having diabetes can take away the joy of a situation,” said Nick about the reality of diabetes. “It’s a full life change.”
By doing the interview, Jonas hopes to help raise awareness about diabetes, motivate others and ensure they know they are not alone.
“Nick Jonas is just 16 but he is a larger than life player in our culture and has a unique opportunity to share his story to benefit so many,” said Howard Steinberg, founder and CEO of dLife. “He deserves credit for seizing this moment to help others. The reality is that every single American is touched by diabetes in some way. DLife’s goal in interviewing Nick Jonas is to ensure he empowers the people that really need to hear his message.”
An advance screening of the Jonas interview will be avilable one week prior to its premiere on CNBC for dLife members at dLife.com/nickjonas.
Experts discuss medication adherence
WASHINGTON Poor adherence to medication regimens could counteract the benefits of healthcare reform, a panel of experts concluded Wednesday.
The panel — which brings together experts from GlaxoSmithKline, the National Association of Chain Drug Stores Foundation, the National Consumer’s League and the Pharmaceutical Research and Manufacturers of America — hopes to open a dialogue about medication adherence with between experts from the health, medical, insurance, business, employer, academic and government sectors.
“To date, medication adherence hasn’t been a prominent part of the debate,” conference moderator and founding editor of the journal Health Affairs John Iglehart said in a statement. “But no matter what shape health reform takes, it will ultimately be more successful if it supports the education and motivation of patients to properly follow their medication regimens.”
Participants in the panel will receive briefings on two new research efforts on medication adherence conducted by Avalere Health and the RAND Corp., respectively, using findings from the studies to guide the creation of policy and public education recommendations.
As many as 80% of patients may not be adhering to their medication regimens, according to research, resulting in adverse consequences and draining $100 billion to $300 billion from the healthcare system every year.
MiddleBrook Pharmaceuticals develops copay program for Moxatag
WESTLAKE, Texas A company making a long-acting formulation of a common antibiotic has announced a program to minimize the drug’s cost to consumers.
MiddleBrook Pharmaceuticals announced Wednesday a $20 maximum copay program for Moxatag (amoxicillin) extended-release tablets in the 775 mg strength, designed to keep the drug’s cost to patients at $20 or less. The company said it will field 300 representatives and district managers to begin supplying physicians with voucher cards for the program.
“In this tough economy, we recognize the need to improve Moxatag’s affordability to the patient,” MiddleBrook president and CEO John Thievon said in a statement. “This $20 maximum copay program will replace our current $15 point-of-sale copay check program, which has been in place since Moxatag’s launch.”